A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through the Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; pharmacy data, consumer loyalty, and analytics services; and health communications, programs, and consultancy services. It also offers community-based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five-step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; dog and cat food, and treats; and surgical devices and medical consumables. Further, it provides pet nutrition, treats, clean-up, and grooming products and accessories; supplies pet medicines and other products to veterinary clinics and specialty retailers; manufactures and supplies dog rolls; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
Financial Summary
| Share Statistics | EBOSY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,523.7 | $1,785.4 | 57% |
|
| Shares Out (Mil) | 143.4 | 71.5 | 70% |
|
| Institutional Ownership | 49.9% | 86.0% | 27% |
|
| Float (Mil) | 196.9 | 55.7 | 74% |
|
| Beta | 0.15 | 0.74 | 11% |
|
| Avg Daily Volume (000s) | 1 | 402 | 4% |
|
| Price Change (52-week) |
na | 78.5% | na |
|
| Growth | EBOSY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.2% | 10.7% | 42% |
|
| Net Income (5yr) | 2.3% | (0.5%) | 43% |
|
| EPS (5yr) | (2.3%) | 2.1% | 28 |
|
| Dividends (5yr) | 2.0% | 0.0% | 73% |
|
| Cash Flow (5yr) | 20.9% | (17.5%) | 80% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EBOSY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9,330 | $1,490 | 83% |
|
| Net Income (TTM) (Mil) | $156 | $24 | 65% |
|
| EPS (TTM) | $0.760 | $0.200 | 58% |
|
| Operating Cash Flow (TTM) (Mil) | $241 | $151 | 61% |
|
| Net Cash Flow (TTM) (Mil) | $36 | $9 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $1,207 | $338 | 68% |
|
| Enterprise Value (Q1) (Mil) | $3,915 | $2,334 | 58% |
|
| Valuation | EBOSY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.96 | na |
|
| P/E | na | 25.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EBOSY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 12.9% | 27.9% | 12% |
|
| Net Margin | 1.7% | 1.3% | 37% |
|
| ROA | 3.1% | 2.2% | 62% |
|
| ROE | 8.4% | 6.8% | 52% |
|
| Liabilities to Assets | 65.4% | 60.5% | 61% |
|
| F-Score | na | 5 | na |
|
EBOS Group Limited did not pass any screens on 9/4/2026.
